Is EXPO a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Reactive and disputes demand, with revenue (ttm) at ~$567M. The bear case rests on exponent's output is entirely dependent on attracting and retaining specialized PhD-level and engineering talent, so wage inflation, attrition, or hiring shortfalls directly pressure capacity and margins. Analysts covering it are spread from $72.00 to $90.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Exponent's output is entirely dependent on attracting and retaining specialized PhD-level and engineering talent, so wage inflation, attrition, or hiring shortfalls directly pressure capacity and margins. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $72.00, +0.2% from the $71.85 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Reactive and disputes demand. A large share of Exponent's work is reactive: product failures, accidents, recalls, and litigation that clients cannot defer. The most optimistic analyst target on EXPO is $90.00, +25.3% from the $71.85 price. That figure is only reachable if this thesis works close to its best case.

Exponent's output is entirely dependent on attracting and retaining specialized PhD-level and engineering talent, so wage inflation, attrition, or hiring shortfalls directly pressure capacity and margins. Utilization and billable hours can swing with client budgets and the timing of large disputes, making quarterly results lumpy. A meaningful portion of revenue is concentrated in a relatively small number of large engagements and clients, adding volatility. The stock also trades at a premium multiple (about 32x trailing and 26x forward earnings as of October 2026), so even modest growth disappointments can drive outsized share-price moves. Broader legal, regulatory, or economic slowdowns that reduce litigation and consulting spend would weigh on demand. Recent results have also lost the habit of beating: Q1 2026 EPS came in slightly below consensus and Q2 merely matched it, so the October 29 report (consensus about $0.62) arrives after an 18% three-month rally. The most pessimistic published target is $72.00, +0.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Reactive and disputes demand) stalling in the reported numbers rather than in the narrative, the risk above (exponent's output is entirely dependent on attracting and retaining specialized PhD-level and engineering talent, so wage inflation, attrition, or hiring shortfalls directly pressure capacity and margins) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Exponent is an engineering and scientific consulting firm that investigates why products, structures, and systems fail and provides expert analysis for litigation, product safety, and risk management. Clients include corporations, law firms, insurers, and government agencies across many industries.

It bills clients for the time of its scientists and engineers on a project basis, so revenue is driven by billable hours, staff utilization, and billing rates. It is a capital-light, people-based model with high margins and little need for heavy physical assets.

Yes. Exponent is consistently profitable with EBITDA margins around 28% of net revenues. In Q1 2026 it reported net income of about $30 million and diluted EPS near $0.59, Q2 2026 net income was about $29 million with EPS of $0.60, and trailing net income is about $112 million. It generates strong free cash flow.